Janssen's books disappointing sales of Genmab-developed Darzalex
Fourth-quarter sales figures from cancer drug Darzalex, which was developed by Danish biotech company Genmab, did not meet analysts’ expectations.
by marketwire, translated by daniel pedersen
Johnson & Johnson has just published its fourth-quarter report, which exceeded expectations for the company’s earnings per share.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
DNB Markets recommends to sell Genmab stock
For subscribers
